Free Trial

bioAffinity Technologies Q4 2024 Earnings Report

bioAffinity Technologies logo
$0.89 -0.20 (-18.35%)
As of 04/2/2025 04:00 PM Eastern

bioAffinity Technologies EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$2.20 million
Expected Revenue
$2.42 million
Beat/Miss
Missed by -$216.00 thousand
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

bioAffinity Technologies Earnings Headlines

Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat